VTRS250117P20000
- 8.50
- 0.000.00%
Viatris Newsroom
Viatris Inc. Stock Falls Tuesday, Underperforms Market
Viatris Issues Statement Regarding Receipt Of Warning Letter And Import Alert For Indore, India Facility; The Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into The U.S. Until The Warning Letter Is Lifted
Express News | Viatris Inc: There Could Be Potential for Additional Exceptions by FDA Based on Further Discussions Related to Import Alert
Express News | Viatris: Engaged Independent Third-Party Subject Matter Experts to Support Remediation Plan
Express News | Viatris: Necessary Corrective and Preventive Actions Well Underway, Including but Not Limited to Related Personnel Actions
Express News | Viatris: Do Not Anticipate Actions to Impact Current 2024 Financial Guidance Ranges
Express News | Viatris Inc: Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into U.S. Until Warning Letter Is Lifted
Express News | Viatris Statement Regarding Receipt of Warning Letter and Import Alert for Indore, India Facility
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Daily short sale tracking: Palantir's short volume increased by 51 million, with a short sale ratio of 23%
UBS Says 'Underweight the Names With High China Exposure'
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn?
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today